RecruitingNot ApplicableNCT06164314

Perioperative Dexmedetomidine on Postoperative Delirium in Patients With Brain Tumors

Effect of Perioperative Dexmedetomidine on Postoperative Delirium in Patients With Brain Tumors: a Randomized Placebo-controlled Trial


Sponsor

Beijing Tiantan Hospital

Enrollment

366 participants

Start Date

Jan 25, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Neurosurgery is a risk factor for delirium. Dexmedetomidine might reduce delirium by reducing neuroinflammation, improving postoperative analgesia and sleep quality. The the primary hypothesis is that perioperative administration of dexmedetomidine can reduce the incidence of postoperative delirium


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether giving dexmedetomidine (a sedative and pain-reducing medication) around the time of surgery helps prevent postoperative delirium — a state of sudden confusion that is common after surgery in older patients. It is tested in elderly patients having major non-cardiac surgery. **You may be eligible if...** - You are 65 years or older - You are scheduled for major non-cardiac surgery requiring general anesthesia - You are at risk for postoperative delirium **You may NOT be eligible if...** - You have severe heart conditions (very slow heart rate, heart block, or low blood pressure) - You have serious liver or kidney disease affecting drug clearance - You are already taking sedative medications that interact with dexmedetomidine - You have a pre-existing dementia or altered mental state before surgery Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDexmedetomidine

In Dex group, dexmedetomidine will continue to be used during and after surgery, with a infusion of 0.4ug/kg/ h from anesthesia induction to dural closure, and then 0.08ug/kg/ h to 48 hours postoperatively.In placebo group, equivalent normal saline will be injected during operation, and the intravenous analgesia pump will not contain dexmedetomidine after operation


Locations(1)

Beijing Tiantan Hospital

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06164314


Related Trials